Comparison of CA 242 Tumor Marker in Digestive Tract Diseases
Author Information
Author(s): P. Kuusela, C. Haglund, P.J. Roberts
Primary Institution: University of Helsinki
Hypothesis
The study aims to compare the levels of CA 242 with other tumor markers in patients with digestive tract diseases.
Conclusion
CA 242 is a promising new tumor marker that may be useful in diagnosing pancreatic, biliary, and colorectal cancers.
Supporting Evidence
- 68% of patients with pancreatic and biliary cancers had elevated CA 242 levels.
- CA 242 detected more Dukes A-B carcinomas than CEA.
- 55% of patients with colorectal cancer had elevated CA 242 levels.
Takeaway
CA 242 is a new test that helps doctors find certain types of cancer in the stomach and intestines, and it works better than some older tests.
Methodology
Serum levels of CA 242, CA 19-9, CA 50, and CEA were measured in patients with digestive tract malignancies and benign diseases.
Potential Biases
Potential for falsely positive results in benign conditions affecting the interpretation of CA 242 levels.
Limitations
The study did not include patients receiving chemotherapy, which may limit the generalizability of the findings.
Participant Demographics
185 patients with malignancies and 123 patients with benign digestive tract diseases.
Want to read the original?
Access the complete publication on the publisher's website